Trials / Completed
CompletedNCT00136292
Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics
An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic therapy. The tolerability of a single dose of daptomycin in these patients will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | daptomycin |
Timeline
- Start date
- 2005-08-24
- Primary completion
- 2006-08-01
- Completion
- 2006-08-09
- First posted
- 2005-08-29
- Last updated
- 2020-03-11
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00136292. Inclusion in this directory is not an endorsement.